

**SUBMITTAL TO THE BOARD OF SUPERVISORS
COUNTY OF RIVERSIDE, STATE OF CALIFORNIA**

836



SUBMITTAL DATE:
June 11, 2014

FROM: Riverside County Regional Medical Center (RCRMC)

SUBJECT: Riverside County Regional Medical Center (RCRMC) to enter into a three-year agreement with Baxter Healthcare through GPO pricing to purchase frozen antibiotics that will include a freezer to store medications. [All District; \$1,890,000; Hospital Enterprise Fund]

RECOMMENDED MOTION: That the Board of Supervisors:

1. Approve and execute the agreement with Baxter Healthcare without seeking competitive bids for a term of three consecutive years, using Group Purchasing Organization (GPO) pricing not to exceed \$630,000 annually;
2. Authorize the County Purchasing Agent, in accordance with Ordinance No. 459 to sign amendments that do not change the substantive terms of the agreement and allow the Purchasing Agent to increase the compensation provision that do not exceed the annual CPI rates.

Lowell Johnson

Lowell Johnson
Interim CEO

FINANCIAL DATA	Current Fiscal Year	Next Fiscal Year	Total Cost	Ongoing Cost	POLICY/CONSENT (per Exec. Office)
COST	\$ 630,000	\$ 630,000	\$ 1,890,000	\$	Consent <input type="checkbox"/> Policy <input checked="" type="checkbox"/>
NET COUNTY COST	\$	\$	\$	\$	

SOURCE OF FUNDS: Hospital Enterprise Fund

Budget Adjustment: No

For Fiscal Year: 2014/2015

C.E.O. RECOMMENDATION:

APPROVE

BY: *Debra Cournoyer*
Debra Cournoyer

County Executive Office Signature

MINUTES OF THE BOARD OF SUPERVISORS

On motion of Supervisor Jeffries, seconded by Supervisor Benoit and duly carried by unanimous vote, IT WAS ORDERED that the above matter is approved as recommended.

Ayes: Jeffries, Tavaglione, Stone, Benoit and Ashley
Nays: None
Absent: None
Date: July 1, 2014
xc: RCRMC

Kecia Harper-Ihem
Clerk of the Board

By: *[Signature]*
Deputy

Prev. Agn. Ref.:

District: All

Agenda Number:

3-39

FORM APPROVED BY COUNTY COUNSEL
DATE
BY: *[Signature]*
NEAR KLINIS
Departmental Conference

Purchasing: *[Signature]*
Mark Seller, Assistant Director

☐ A-30
☐ Positions Added
☐ 4/5 Vote
☐ Change Order

SUBMITTAL TO THE BOARD OF SUPERVISORS, COUNTY OF RIVERSIDE, STATE OF CALIFORNIA
FORM 11: Riverside County Regional Medical Center (RCRMC) to enter into a multi-year agreement with Baxter Healthcare through GPO pricing to purchase frozen antibiotics that will include a freezer to store medications. [All District; \$1,890,000; Hospital Enterprise Fund]

DATE: June 11, 2014

PAGE: 2 of 2

BACKGROUND:

Summary

The benefits of GPO pricing helps members obtain lower costs, enhance revenue and deliver quantifiable savings. This is attained by combining the volume of the entire GPO members, ultimately achieving the largest volume discounts and favorable terms. RCRMC has a current contract with Baxter Healthcare to use their proprietary frozen medication products, premixed frozen IVPB (intravenous piggyback – i.v. short-term infusion) antibiotics for their patients.

The current freezer that RCRMC originally purchased from Baxter Healthcare to store the medication failed and the RCRMC Plant Operations Department (Plant Ops) has determined it cannot be repaired. RCRMC contacted several vendors and determined Baxter Healthcare is the only vendor that supplies these frozen premixed drugs.

Impact on Residents and Businesses

This service impacts the patients residing in Riverside County that are receiving care from RCRMC. No impact on surrounding businesses.

Contract History and Price Reasonableness

RCRMC has a current contract with Baxter Healthcare to use their proprietary frozen medications products for the patients of RCRMC through GPO pricing. The benefits of GPO pricing helps members obtain lower costs, enhance revenue and deliver quantifiable savings. This is attained by combining the volume of the entire GPO members, ultimately achieving the largest volume discounts and favorable terms.

The County has been able to negotiate a three-year, multi-year contract with Baxter for a minimum committed volume in the amount of \$39,638.00 of frozen antibiotics that will include a freezer to store their frozen products at no additional expense to the County if the County commits to the three (3) year contract. RCRMC would only need to fulfill Baxter's contract requirements by purchasing \$39,638.00 of the pharmaceuticals at the GPO pricing. The pharmacy, at current usage levels, would meet that dollar amount of the contract in approximately 60 days; fulfilling the purchase commitment in order to receive the freezer at no charge. The price of the frozen products is exactly the same as if RCRMC did not enter into this agreement for the freezer. Once the contracted amount of product has been purchased, the freezer becomes the property of RCRMC with no further obligation to purchase any products from Baxter healthcare. The freezer is a pharmaceutical grade two door freezer that has been reviewed and approved by Plant Ops and has no OSHPD concerns.

If the Baxter agreement is not executed, the only outcome is that RCRMC will not receive this needed freezer. The alternative is to spend approximately \$8,000 for a pharmaceutical grade two-door freezer and continue to pay the same price for these proprietary frozen medications products. The Baxter agreement will save the County that \$8,000.

Date: June 6, 2014

From: Lowell Johnson, CEO, Riverside County Regional Medical Center

To: Purchasing Agent

Subject: Sole Source Procurement;
Request for Baxter Healthcare Frozen Pharmaceuticals through a GPO contract.

The below information is provided in support of my Department requesting approval for a sole source. Outside of a duly declared emergency, the time to develop a statement of work or specifications is not in itself justification for sole source.

1. **Supply/Service being requested:** Agreement to purchase frozen antibiotics that would include a pharmaceutical grade freezer from Baxter Healthcare
2. **Supplier being requested:** Baxter Healthcare
3. **Alternative suppliers that can or might be able to provide supply/service:** We purchase frozen medications proprietary products from vendor Baxter Healthcare from our GPO contract. The frozen products are not available from any other vendor. The current freezer, which has failed and cannot be repaired, was purchased from Baxter.
4. **Extent of market search conducted:** None as this is tied to the frozen product which is only available from Baxter.
5. **Unique features of the supply/service being requested from this supplier, which no alternative supplier can provide.** Riverside County Regional Medical Center (RCRMC) has a current contract with Baxter Healthcare to use their proprietary frozen medications products for the patients of RCRMC. The Pharmacy Director has been able to negotiate a contract with Baxter to acquire a freezer to store their frozen products for no additional expense to the County. RCRMC would need to fulfill the contract requirements by purchasing a certain dollar amount of frozen product, at the GPO pricing, as stated in the Baxter agreement. The pharmacy, at current usage levels, would meet the dollar amount in the contract in approximately 60 days. The price of the frozen products is exactly the same as if we did not enter into this agreement for the freezer. Once the contracted amount of product has been purchased, the freezer becomes the property of RCRMC with no further obligation to purchase any products from Baxter Healthcare. The freezer is a pharmaceutical grade two door freezer.
The alternative is to spend approximately \$8,000 for a pharmaceutical grade two door freezer and continue to pay the same price for the frozen antibiotic products. The agreement will save the County that \$8,000.
6. **Reasons why my department requires these unique features and what benefit will accrue to the county:** We currently purchase frozen medication from Baxter Healthcare the freezer requested in the agreement would meet the requirements needed to store this medication. This freezer is needed as soon as possible as the current freezer is no longer working.

7. **Price Reasonableness including purchase price and any ongoing maintenance or ancillary costs from the supplier:** RCRMC has a current contract with Baxter Healthcare to use their proprietary frozen medication products for the patients of RCRMC through Group Purchasing Organization (GPO) pricing, not to exceed \$630,000 annually, \$1,890,000 for the full three (3) years.

The County has been able to negotiate a three-year, multi-year contract with Baxter for a minimum committed volume in the amount of \$39,638.00 of frozen antibiotics that will include a freezer to store their frozen products at no additional expense to the County if the County commits to the three year contract. RCRMC would need to fulfill Baxter's contract requirements by purchasing \$39,638.00 of the pharmaceuticals at the GPO pricing. The pharmacy, at current usage levels, would meet that dollar amount of the contract in approximately 60 days. The price of the frozen products is exactly the same as if RCRMC did not enter into this agreement for the freezer. Once the contracted amount of product has been purchased, the freezer becomes the property of RCRMC with no further obligation to purchase any products from Baxter healthcare. The freezer is a pharmaceutical grade two door freezer that has been reviewed and approved by Plant Ops and has no OSHPD concerns.

If the Baxter agreement is not executed, the only outcome is that RCRMC will not receive this needed freezer. The alternative is to spend approximately \$8,000 for a pharmaceutical grade two-door freezer and continue to pay the same price for these proprietary frozen medications products. The Baxter agreement will save the County that \$8,000.

8. **Does moving forward on this product or service further obligate the county to future similar contractual arrangements or any ongoing costs affiliated with this sole source? (Maintenance, support, or upgrades, if so, please explain).** No
9. **Period of Performance:** Multiyear for a term of three (3) years, effective (date), using GPO pricing not to exceed \$630,000 annually. Upon approval, contract will be fulfilled in approximately 60 days.



Department Head Signature

10 June 2014

Date

Purchasing Department Comments:

Approve

Approve with Condition/s

Disapprove

Not to exceed: \$1,890,000.00 total amount for the 3 consecutive years. Annual Amount of \$630,000.00



Purchasing Agent

6-16-14
Date

15-034
Approval Number
(Reference on Purchasing Documents)



Baxter Healthcare Corporation
William Graham Building 1-2N
25212 West Illinois Route 120
Round Lake, IL 60073
Attention: Lori Rumer
Date: March 11, 2014

WHEN DOCUMENT IS FULLY EXECUTED RETURN
CLERK'S COPY
to Riverside County Clerk of the Board, Stop 1010
Post Office Box 1147, Riverside, Ca 92502-1147
Thank you.

Temperature Control Equipment Agreement

Customer: Riverside County Regional Medical Center

Address: 26520 Cactus Avenue

City, State, Zip: Moreno Valley, CA 92555

Account #: 34136959

Attention: Kelleen Rankin

Phone #: 951-486-4537

ShipTo: Riverside County Regional Medical Center

Address: 26520 Cactus Avenue

City, State, Zip: Moreno Valley, CA 92555

Account #: 34136959

Attention: Kelleen Rankin

Phone #: 951-486-4537

Term: 36 Months

This Temperature Control Equipment Agreement ("Agreement") is between Baxter Healthcare Corporation, a Delaware corporation, on behalf of itself and its affiliates ("Baxter") and Riverside County Regional Medical Center ("Customer"). Subject to the provisions of this Agreement, Baxter shall provide to Customer the equipment listed on Schedule A and/or Schedule A-1 attached hereto ("Equipment"). The proposed arrangement contemplated under this Agreement will be available for Customer's consideration for ninety (90) days. In the event this Agreement is not executed by Customer within ninety (90) days after presentation to Customer, this Agreement will no longer be accepted by Baxter.

1. DATES. The "Effective Date" of this Agreement shall be five (5) business days after the date that Baxter countersigns this Agreement, and the "Expiration Date" shall be thirty-six (36) months after the Effective Date.

2. REQUIREMENTS. By signing this Agreement, Customer agrees to purchase a Minimum Committed Volume ("Total MCV") in the amount of \$39,638.00 of products reflected on Schedule B attached hereto ("Product") during the term of this Agreement. For purposes of evaluating ongoing compliance with the Total MCV, the Total MCV is divided into three (3) twelve (12) month periods during the term of this Agreement (each, an "Annual MCV"), but all purchases of Product shall apply to satisfaction of the Total MCV, and excess purchases of Product in one contract year shall count toward future Annual MCV measurement and the Total MCV requirement. For purposes of this Agreement, "purchases" shall reflect the net (less any returns and other credits) invoice price for each Product set forth on Schedule B that is ordered by and invoiced to Customer. With respect to frozen drug products offered by Baxter but manufactured and billed by a third party drug manufacturer ("Non-Baxter Billed Product"), Customer will receive credit in the amount of \$2.50 per unit of Non-Baxter Billed Product purchased toward Customer's Total MCV under this Agreement; provided that Customer purchases sufficient Baxter billed Product to cover the cost of the Equipment listed herein. The purpose of such commitment is for purchases of applicable Product to reimburse Baxter for the cost of Equipment (as defined below) provided hereunder to Customer that is necessary to maintain appropriate temperature levels of such Product. Baxter and Customer acknowledge that Customer must store the Product below certain temperature levels in order to maintain the Product integrity, as required by the Food and Drug Administration ("FDA"). Based upon Customer's purchasing commitments for Product listed on Schedule B, Baxter will provide Customer with the Equipment set forth in Schedule A and/or Schedule A-1 with the understanding and on the condition that each piece of Equipment will be used solely to store and maintain applicable Product in accordance with FDA requirements, and that the Equipment will be used for no other purpose by Customer and therefore will provide no independent value to Customer, during the term of this Agreement. Pricing for such Schedule B Products shall be in accordance with any applicable agreement in effect between Customer and Baxter. If a committed agreement other than a Temperature Control Equipment Agreement or similar agreement is already in effect between Baxter and Customer, the Annual MCV and Total MCV hereunder shall count toward (and shall not be in addition to) the units committed to be purchased by Customer under any such committed agreement; provided, however, that in the event Customer has any other Temperature Control Equipment Agreement or similar agreement in place, Customer's obligations under such separate agreement shall be in addition to Customer's

JUL 01 2014

339

obligations under this Agreement. Customer acknowledges that the value of each piece of Equipment is as shown in the Equipment Model table on Schedule A.

3. DISCLOSURES. Customer and Baxter intend that this Agreement shall be administered in accordance with the provisions of the federal Anti-Kickback Statute (42, U.S.C. § 1320a-7b(b)). Any discounts and rebates received by Customer with respect to Products under this Agreement, may be considered "discounts or other reductions in price" under the Anti-Kickback Statute, Section 1128B(b)(3)(A) of the Social Security Act [42 U.S.C. § 1320a-7b(b)(3)(A)]. To the extent required by the Anti-Kickback Statute or the Discount Safe Harbor regulations, 42 C.F.R § 1001.952(h) et seq., Customer shall fully and accurately disclose such discounts and other reductions in price in accordance with the applicable state or federal cost reporting requirements, including, without limitation, disclosing and accurately reflecting where appropriate, and as appropriate, to the applicable reimbursement methodology. Baxter will provide Customer with sales and discount information to allow Customer to comply with this Section and the discount safe harbor, including sufficient rebate and pricing information to enable Customer to accurately report its actual costs for all purchases of Baxter Products and services made pursuant to this Agreement. The total charges for the Products purchased under this Agreement shall be the contract price less any such discounts, including rebates.

4. DEFAULT. The value of each item of Equipment shall be depreciated by Baxter during the term of this Agreement on a straight line basis over thirty-six (36) months. Baxter shall monitor Customer's Product purchases on an annual basis during the term of this Agreement. Upon completion of Baxter's annual review, Baxter shall send a statement to non-compliant Customers that will provide the applicable Annual MCV commitment, and the Annual MCV purchases to date. In the event Customer fails to satisfy the Annual MCV purchase requirement in the third year of this Agreement, Customer shall issue to Baxter a Purchase Order number to be used in the preparation of an invoice for payment in the amount necessary to pay the full value of the Equipment including any affiliated charges such as shipping and state taxes, within thirty (30) days following the invoice date. In the event Customer fails to pay any such amount within the specified payment period: (i) interest shall accrue at a rate of 1.5% per month (or such lower maximum interest permitted under applicable law) on the outstanding principal beginning the day after such principal payment is due to Baxter; and (ii) Baxter shall be entitled to pursue all necessary and appropriate collection remedies; and (iii) Customer agrees to pay all such interest, and reimburse Baxter for all reasonable fees and costs of collection, in addition to the amount of the principal obligation and accrued interest.

5. OWNERSHIP OF EQUIPMENT. Baxter is the owner of the Equipment and has title to the Equipment. Customer will sign informational UCC filings if Baxter wishes to file such to give notice of Baxter's ownership. Upon expiration of the Term of the Agreement, and upon satisfaction of all Customer's obligations, Baxter will convey title of the Equipment to Customer. From the date of receipt of the Equipment, in the event of loss, theft, or destruction of the Equipment, Customer will be charged the full cost of replacing the Equipment and Customer shall continue to be obligated to the requirements stated under Section 2. Customer may, at Customer's sole cost and expense, keep the Equipment fully insured against loss from the date of receipt of the Equipment until title transfers to Customer pursuant to the terms of this Agreement and to have Baxter named as loss payee on all such policies.

6. TAXES AND OTHER CHARGES. If applicable, Customer agrees to pay all federal, state, and local sales taxes, use, excise and/or gross receipt tax, license and registration fees, and all similar costs based on Customer's use of the Equipment resulting from transactions with Baxter regardless of legal liability for the tax. Baxter will pay all property taxes based on the Equipment to the appropriate taxing authority and Customer will reimburse Baxter for all such payments promptly on request.

7. DISCLAIMER OF WARRANTIES. Baxter will provide to Customer any warranty provided by the manufacturer of the Equipment; more specific warranties may accompany the Equipment. Customer is solely responsible for arranging and paying all costs associated with all service and repairs required on the Equipment after expiration of the applicable warranty period, and for arranging for warranty repairs during any applicable warranty period. BAXTER MAKES NO OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. BAXTER SHALL HAVE NO LIABILITY TO CUSTOMER FOR SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES.

8. LOCATION AND USE OF EQUIPMENT. From the date of receipt of the Equipment, Customer agrees to use the Equipment only for the purposes and according to the instructions indicated on the labeling or otherwise included with the Equipment, and for storage of Product at the location(s) purchasing and using the Product specified in this Agreement; provided that Customer may use the Equipment in connection with the storage or thawing of other refrigerated medical products as long as Customer appropriately follows all storage and handling procedures related to the Products and such other refrigerated medical products. Customer shall not modify the Equipment without Baxter's prior written consent, and the Equipment shall remain personal property at all times, regardless of how it is attached or installed. Customer shall be responsible for all consequences of transfer or possession of the Equipment to any other party and for the continued performance of all its obligations under this Agreement after any such transfer.

9. ASSIGNMENT. Customer has no right to sell, transfer, assign or sublease the Equipment or this Agreement without Baxter's prior written consent.

10. RESPONSIBILITY. Customer acknowledges that the selection, possession, operation and use of the Equipment is solely the Customer's responsibility. Therefore, Customer shall be responsible for all liabilities, costs and expenses, including, but not limited to, loss of Product, lawsuits and claims for personal injury and property damage to the extent of, and arising out of, Customer's selection, possession, operation or use of the Equipment. Customer agrees to hold Baxter harmless against any and all damages or injury associated with the selection, possession, operation and use of the Equipment.

11. COMPLIANCE WITH LAWS. Each party shall comply with all federal, state and local laws, ordinances, codes, rules and regulations that in any way affect the party's performance of this Agreement.

12. MISCELLANEOUS. This Agreement is the entire agreement between Baxter and Customer relating to the Equipment and, in the event of conflict, supersedes all prior agreements, all purchase orders, acknowledgment forms or other written documents submitted by Customer, and all invoices of Baxter. It shall not be changed or amended except by written agreement executed by both parties and this Agreement shall not be valid or binding unless approved and accepted by Baxter at its home office. This Agreement shall be governed by and interpreted in accordance with Illinois law.

13. CONFIDENTIALITY. Each party shall, for a period of five (5) years from the date of receipt in writing of any trade secrets or other confidential information that is labeled as "Confidential" ("Information"), hold such Information in confidence and not disclose it to a third party without the prior written consent of the other party. Information shall include any other information that is noted as "Confidential" at the time of disclosure and reduced to writing and labeled as "Confidential" by the disclosing party within ten (10) business days after time of disclosure. Information also includes any and all information regarding the price or cost of Equipment provided to Customer under this Agreement, and Customer agrees not to share such Information with any third party other than as required for Medicare and other federal and state healthcare program(s) price reporting obligations and applicable discount disclosure requirements. Each party will take all reasonable precautions, including adequate procedures and disciplines, to safeguard the confidential nature of such Information. Baxter agrees that the same procedures which Customer would use to protect its own confidential and proprietary information shall be deemed adequate to satisfy Customer's obligation of confidentiality hereunder.

Each party's obligation to maintain the Information disclosed in confidence hereunder shall not apply if the Information:

- a) Is in the public domain at the time it is received by the receiving party; or
- b) Becomes rightfully publicly known; or
- c) Is furnished by the disclosing party to others without restrictions regarding the right to use or disclose; or
- d) Is known to the receiving party at the time the Information is received or becomes known to the receiving party from a source other than the disclosing party, which source did not receive such information directly or indirectly from the disclosing party; or
- e) Is approved for release in writing by the disclosing party; or
- f) Is independently discovered, created, or developed by the receiving party without the use of or reference to the Information, as evidenced by the receiving party's written records; or
- g) The Information is subject to disclosure by operation of law, legal process, or the reasonable request of a government agency, in which event the receiving party shall notify the disclosing party prior to making any such disclosure.

Promptly after any termination or expiration of this Agreement each party shall, unless otherwise agreed in writing, deliver to the other party any materials (including discs) containing other party's Information.

14. NON-APPROPRIATION CLAUSE. Notwithstanding any other provision of this Agreement; all obligations of the County under this Agreement which require the expenditure of funds are conditioned on the availability of funds appropriated for that purpose.

If Customer is subject to non-appropriation of funds, then Customer represents and warrants that it shall not purchase, lease, rent or receive at no charge, equipment which performs the same function as, or functions taking the place of, those performed by the Equipment, and shall not permit such functions to be performed by its own employees or by any agency or entity affiliated with or hired by Customer for the balance of the fiscal period in which such termination occurs or the next succeeding fiscal period thereafter, from any vendor or supplier other than Baxter and (ii) that it shall not, during the lease period, give priority to the application of funds to any other functionally similar equipment.

By providing an electronic or handwritten signature, the individual signing the Agreement on behalf of the Customer represents and warrants he or she is authorized to sign this Agreement and has full authority to bind Customer to the terms and conditions herein.

IN WITNESS WHEREOF, the undersigned duly authorized representatives of the parties have executed this Agreement on the date below.

Riverside County Regional Medical Center

Baxter Healthcare Corporation

By: Jeff Stone
Print Name: JEFF STONE
Title: CHAIRMAN, BOARD OF SUPERVISORS
Date: JUL 01 2014
Email Address: _____

By: _____
Print Name: _____
Title: _____
Date: _____
Contract Number: _____

HOME OFFICE ONLY

FORM APPROVED COUNTY COUNSEL

BY: NEAL R. KIPNIS DATE 6/18/14

ATTEST:

KECIA HARPER-IHEM, Clerk

By: [Signature]
DEPUTY

Schedule A

Model Table Equipment

Equipment Model & Description	Equipment Value	Number of Units
BAXFRZ1D One Door Freezer	\$6,576.96	1

Schedule B

Baxter Billed Products

Product Code	NDC Number	Description
2G3503	0338-3503-41	1G CEFAZOLIN INJ, ISO-OSMOTIC
2G3504	0338-5002-41	1G CEFTRIAZONE SOD INJ
2G3505	0338-5003-41	2G CEFTRIAZONE SOD INJ
2G3518	0039-0037-05	1G CLAFORAN (CEFOTAXIME SOD INJ)
2G3519	0039-0038-05	2G CLAFORAN (CEFOTAXIME SOD INJ)
2G3538	0338-1013-41	1G BACTOCILL (OXACILLIN SOD INJ)
2G3539	0338-1015-41	2G BACTOCILL (OXACILLIN SOD INJ)
2G3540	0338-1017-41	1G NALLPEN (NAFCILLIN SOD INJ)
2G3542	0338-1021-41	1MU PENICILLIN G POTASSIUM INJ
2G3543	0338-1023-41	2MU PENICILLIN G POTASSIUM INJ
2G3544	0338-1025-41	3MU PENICILLIN G POTASSIUM INJ
2G3551	0338-3551-48	VANCOMYCIN INJ 100ML (500MG)
2G3580	0338-3580-48	VANCOMYCIN INJ 150ML (750MG)
2G3552	0338-3552-48	VANCOMYCIN INJ 200ML (1G)
2G3556	0338-1019-48	2G IN 100ML NAFCILLIN SODIUM INJ
2G3578	0338-1301-41	1G CEFEPIME INJECTION
2G3579	0338-1301-48	2G CEFEPIME INJECTION

B

Non-Baxter Billed Products

Product Code	NDC Number	Description
2G3506	67457-189-01	MEFOXIN 1G
2G3507	67457-216-50	MEFOXIN 2G
2G3527	51479-048-01	AZACTAM 1G
2G3528	51479-049-01	AZACTAM 2G
2G3535	0173-0412-00	FORTAZ 1G
2G3536	0173-0413-00	FORTAZ 2G
2G3545	0029-6571-31	TIMENTIN 3G
2G3546	0173-0424-00	ZINACEF 750MG
2G3547	0173-0425-00	ZINACEF 1.5G
2G3575	0206-8860-02	ZOSYN 2.25g
2G3576	0206-8861-02	ZOSYN 3.375G
2G3577	0206-8862-02	ZOSYN 4.5G